SAN FRANCISCO, May 8, 2023 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. ((“Olema” or “Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancer, today announced a poster presentation of OP-1250, the total estrogen receptor (ER) antagonist (CERAN) and selective ER The Company’s Remedial Agent (SERD) in development for the treatment of metastatic breast cancer at the upcoming ESMO Breast Cancer Annual Meeting 2023, held May 11-13, 2023 in Berlin, Germany.

Details of the ESMO Breast Cancer Annual Congress 2023 poster presentation can be found here:

A copy of the poster will be made available on Olema’s website at Science Section when presented at the Congress. Abstracts for the posters are available on the ESMO Breast Cancer Annual Congress website Here.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for cancer in women. Olema’s lead product candidate, OP-1250, is a proprietary, orally available small molecule with dual activity as a total estrogen receptor (ER) antagonist (CERAN) and as a selective ER degrader (SERD). It is currently being shown to be more positive both as a single agent in an ongoing Phase 2 clinical trial and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib) in patients with recurrent, locally advanced, or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted Fast Track by the FDA…